To better understand the potential for targeting ATM-deficient lung cancer with PARP inhibitors, we studied the association between PARP inhibitor sensitivity and ATM status in 61 lung adenocarcinoma cell lines from the Genomics of Drug Sensitivity in Cancer (GDSC) project. The gene discussed is PARP1; the disease is lung cancer.